Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
6. |
ECCT/09/09/02 | MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN |
Principal Investigator(s) 1. LUCAS OTIENO TINA 2. MARY HAMEL Site(s) in Kenya 1. KEMRI-CDC, (Siaya county) 2. KEMRI-WRP (Kisumu county) |
View |
7. |
ECCT/16/12/02 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. |
Principal Investigator(s) 1. ISAAC TSIKHUTSU Site(s) in Kenya KEMRI/WRP, KERICHO |
View |
8. |
ECCT/12/09/02 | Reduction of EArly mortaLITY in adults and children Reduction of EArly mortaLITY in HIVinfected adults and children starting antiretroviral therapy (REALITY) |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Wellcome Trust Research Programme (Kilifi county) |
View |
9. |
ECCT/15/06/01 | Pyronaridine-artesunate and artemether-lumefantrine for the treatment of paediatric uncomplicated falciparum malaria in Western Kenya |
Principal Investigator(s) 1. Patrick Sawa Site(s) in Kenya St. Judes Clinic, ICIPE |
View |
10. |
ECCT/08/27/12 | MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection. Protocol No. 110021 - MAL 55 STUDY A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa” |
Principal Investigator(s) 1. Dr. Mary Hamel 2. Dr. Patricia Njuguna 3. Dr. Walter Otieno Site(s) in Kenya 1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county) 2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county) 3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county) |
View |